Esophageal Cancer (EsC)
Conditions
Keywords
Prognostic factors, Treatment strategies, Efficacy comparison, Esophageal cancer
Brief summary
This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.
Interventions
OTHERradiotherapy
Definitive radiotherapy or radiotherapy-based combined modality therapy
DRUGImmunotherapy
Immune checkpoint inhibitors as monotherapy or in combination with other therapies
Radical esophagectomy with or without neoadjuvant/adjuvant therapy
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Waiver of informed consent for deceased or lost-to-follow-up patients (January 2017-March 2024) 2. Voluntary signed informed consent from surviving patients who could be contacted 3. Treatment at Nanfang Hospital, Southern Medical University (January 2017-December 2024) 4. Received antitumor therapy for esophageal cancer 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
Exclusion criteria
1. Concurrent other malignancies 2. Patients deemed ineligible by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the date of treatment initiation to the date of death from any cause,assessed up to 120 months. | The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response ( pCR ) | Perioperative | The absence of residual viable tumor cells in both the primary esophageal tumor and regional lymph nodes after completion of surgery, indicating a complete pathological response. |
| Major Pathological Response Rate (MPR) | Perioperative | The proportion of patients with ≤10% residual viable tumor cells in resected specimens |
| Progression-Free Survival (PFS) | From treatment initiation to disease progression or death, assessed up to 100 months | The duration from treatment start until radiologically confirmed disease progression (per RECIST v1.1) or death from any cause, evaluating therapeutic efficacy in delaying tumor growth. |
Countries
China
Outcome results
None listed